Regenxbio
Regenxbio raises $150M Convertible Note at $2B valuation
Regenxbio: Convertible Note Funding Round
Regenxbio has successfully raised $150M in Convertible Note funding, reaching a valuation of $2B.
Company Overview
Gene therapy delivery platform
Funding Details
The Convertible Note round was led by Third Rock Ventures, with participation from SV Life Sciences, Biomatics Capital Partners.
Company Information
- Headquarters: 9600 Blackwell Road, Rockville, MD 20850
- Founded: 2008
- Employees: 350+
- Category: Biotech
Investment
Regenxbio plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Third Rock Ventures: Verified investor in Convertible Note
- SV Life Sciences: Verified investor in Convertible Note
- Biomatics Capital Partners: Verified investor in Convertible Note
Company Info
Investors (3)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free